At its meeting on 09 January 2023, the Transparency Council adopted Opinion No. 5/2023 on the evaluation of the medicine Libtayo (cemiplimab) under a drug programme “Treatment of patients with advanced basal cell carcinoma of the skin with cemiplimab (ICD-10 C44)”.